3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      LncRNA AC020978 facilitates non–small cell lung cancer progression by interacting with malate dehydrogenase 2 and activating the AKT pathway

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Long non–coding RNA AC020978 (lncRNA AC020978) is an oncogenic regulator of non–small cell lung cancer (NSCLC). However, the function of AC020978 in regulating NSCLC metastasis and the potential molecular mechanism remains largely unknown. In this study, we evaluated the expression levels of AC020978 in a series of NSCLC tissues using FISH assays and found that higher AC020978 expression levels were closely associated with metastasis and unfavorable prognosis. Functional studies showed that AC020978 promoted NSCLC migration and invasion both in vitro and in vivo. Further investigation demonstrated that AC020978 interacted with malate dehydrogenase 2 (MDH2) and maintained MDH2 stability. Knockdown of MDH2 weakened the facilitating effect on cell metastasis and 2‐hydroxyglutarate (2‐HG) metabolism in AC020978‐overexpressed NSCLC cells. RNA sequencing, bioinformatic analysis, and western blotting revealed that AC020978 was associated with the AKT signaling pathway. Taken together, our findings revealed that AC020978 might serve as a prognostic biomarker and activate the AKT pathway by stabilizing MDH2, leading to metastasis and progression of NSCLC.

          Abstract

          We identified the metastasis‐related function of lncRNA AC020978 in NSCLC, which directly interacts with MDH2 and promotes migration and invasion of lung cancer through the AC020978/MDH2/AKT axis.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer statistics, 2019

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2016, were collected by the National Center for Health Statistics. In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2006-2015) was stable in women and declined by approximately 2% per year in men, whereas the cancer death rate (2007-2016) declined annually by 1.4% and 1.8%, respectively. The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak. Although the racial gap in cancer mortality is slowly narrowing, socioeconomic inequalities are widening, with the most notable gaps for the most preventable cancers. For example, compared with the most affluent counties, mortality rates in the poorest counties were 2-fold higher for cervical cancer and 40% higher for male lung and liver cancers during 2012-2016. Some states are home to both the wealthiest and the poorest counties, suggesting the opportunity for more equitable dissemination of effective cancer prevention, early detection, and treatment strategies. A broader application of existing cancer control knowledge with an emphasis on disadvantaged groups would undoubtedly accelerate progress against cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer treatment and survivorship statistics, 2019

            The number of cancer survivors continues to increase in the United States because of the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate every 3 years to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics; and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Data Base are presented for the most prevalent cancer types. Cancer-related and treatment-related short-term, long-term, and late health effects are also briefly described. More than 16.9 million Americans (8.1 million males and 8.8 million females) with a history of cancer were alive on January 1, 2019; this number is projected to reach more than 22.1 million by January 1, 2030 based on the growth and aging of the population alone. The 3 most prevalent cancers in 2019 are prostate (3,650,030), colon and rectum (776,120), and melanoma of the skin (684,470) among males, and breast (3,861,520), uterine corpus (807,860), and colon and rectum (768,650) among females. More than one-half (56%) of survivors were diagnosed within the past 10 years, and almost two-thirds (64%) are aged 65 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by follow-up care providers. Although there are growing numbers of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based resources are needed to optimize care.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The biology and management of non-small cell lung cancer.

              Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
                Bookmark

                Author and article information

                Contributors
                yangh@sumhs.edu.cn
                RJnuclear@126.com
                huanggang@sumhs.edu.cn
                Journal
                Cancer Sci
                Cancer Sci
                10.1111/(ISSN)1349-7006
                CAS
                Cancer Science
                John Wiley and Sons Inc. (Hoboken )
                1347-9032
                1349-7006
                15 September 2021
                November 2021
                : 112
                : 11 ( doiID: 10.1111/cas.v112.11 )
                : 4501-4514
                Affiliations
                [ 1 ] Department of Nuclear Medicine Renji Hospital School of Medicine Shanghai Jiaotong University Shanghai China
                [ 2 ] Department of Nuclear Medicine The Second Affiliated Hospital of Soochow University Suzhou China
                [ 3 ] Shanghai Key Laboratory of Molecular Imaging Shanghai University of Medicine and Health Sciences Shanghai China
                Author notes
                [*] [* ] Correspondence

                Gang Huang and Jianjun Liu, Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.

                Emails: huanggang@ 123456sumhs.edu.cn (GH); RJnuclear@ 123456126.com (JL)

                Hao Yang, Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.

                Email: yangh@ 123456sumhs.edu.cn

                Author information
                https://orcid.org/0000-0003-3071-3186
                Article
                CAS15116
                10.1111/cas.15116
                8586664
                34424600
                97dfad4a-59f3-419e-805d-d206db5d0018
                © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 11 August 2021
                : 10 April 2021
                : 16 August 2021
                Page count
                Figures: 9, Tables: 1, Pages: 0, Words: 6077
                Funding
                Funded by: Shanghai Municipal Education Commission (Class II Plateau Disciplinary ConstructionProgram of Medical Technology of SUMHS, 2018‐2020) , doi 10.13039/501100003395;
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: 81830052
                Award ID: 81530053
                Award ID: 81903065
                Funded by: Shanghai Key Laboratory of Molecular Imaging , doi 10.13039/501100015377;
                Award ID: 18DZ2260400
                Categories
                Original Article
                Original Articles
                Carcinogenesis
                Custom metadata
                2.0
                November 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.9 mode:remove_FC converted:12.11.2021

                Oncology & Radiotherapy
                akt,lncrna,mdh2,metastasis,nsclc
                Oncology & Radiotherapy
                akt, lncrna, mdh2, metastasis, nsclc

                Comments

                Comment on this article